Joe Zakrzewski

Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.

AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs. Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health. For more information, please visit www.an2therapeutics.com.

GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery. The company has developed a small molecule clinical candidate – GC021109 – for a glial target that has two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced. GC021109 is currently being developed primarily as a disease modifying treatment of Alzheimer’s disease; however, its dual phagocytosis and anti-inflammatory actions have the potential to affect other disorders. In addition to its program using GC021109, GliaCure has a pipeline program for the development of therapeutics for astrocytic targets related to additional disorders, such as depression and sleep consolidation.

Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Omnipod products are offered in 25 countries around the globe. HIRING SCAM ALERT Recently, individuals impersonating Insulet Human Resources members have offered fraudulent interviews and job offers to unsuspecting candidates. To help protect you from these scam artists, please be aware that: • Insulet will never interview a candidate over RingCentral, similar messaging apps or social media (i.e. Google Hangouts, WhatsApp, Facebook Messenger, etc.), or via text message. • Insulet will never send a company check or ask an applicant to pay a fee or purchase at home work/training materials in connection with an application for employment. • Insulet will never provide excess money to an applicant and ask the applicant to write a check for repayment. If you have any doubt about a job offer or any other communication purporting to come from Insulet, please reach out to us directly at 978-600-7000. If you receive any type of communication on behalf of Insulet that seems inappropriate or suspicious, please report this activity to: www.iC3.gov or www.stopfraud.gov.

Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.

For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com.

AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs. Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health. For more information, please visit www.an2therapeutics.com.

GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery. The company has developed a small molecule clinical candidate – GC021109 – for a glial target that has two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced. GC021109 is currently being developed primarily as a disease modifying treatment of Alzheimer’s disease; however, its dual phagocytosis and anti-inflammatory actions have the potential to affect other disorders. In addition to its program using GC021109, GliaCure has a pipeline program for the development of therapeutics for astrocytic targets related to additional disorders, such as depression and sleep consolidation.